Solcoseryl injection 5ml 5 vials

Solcoseryl - antihypoxic, cytoprotective, regenerating, membrane stabilizing, angioprotective, wound healing.

Solcoseril is a deproteinized hemodialysate containing a wide range of low molecular weight components of cell mass and serum of dairy calves with a molecular weight of 5000 D, whose properties are currently only partially studied by chemical and pharmacological methods.

In in vitro tests, as well as in preclinical and clinical studies, it was found that Solcoseryl:

• increases reparative and regenerative processes;
• promotes activation of aerobic metabolic processes and oxidative phosphorylation;
• increases oxygen consumption in vitro and stimulates glucose transport to cells under hypoxia and to metabolically depleted cells;
• promotes collagen synthesis (in vitro);
• stimulates cell proliferation and migration (in vitro).

Solcoseryl gel does not contain fats as auxiliary components, so it is easily washed off. Promotes the formation of granulation tissue and elimination of exudate.

Since the advent of fresh granulation and drying of the wound it is recommended to use Solcoseryl ointment containing, as auxiliary components, fats and forming a protective film on the wound surface.

Indications:

• Occlusive peripheral artery disease in Fontaine stages III–IV in patients with contraindications/intolerance to other drugs;
• chronic venous insufficiency, accompanied by trophic disorders (Ulcera cruris), in cases of their persistent course;
• disorders of cerebral metabolism and blood circulation (ischemic and hemorrhagic stroke, craniocerebral trauma).

Contraindications:

Hypersensitivity to one of the components of the drug.

With caution - with a predisposition to allergic reactions.

Suggested Use:

Intravenously or intramuscularly.

In the treatment of occlusive peripheral artery diseases in stages III–IV Fontaine-b / b by 20 ml daily. Perhaps intravenous drip in isotonic sodium chloride solution or 5% glucose solution. The duration of therapy is up to 4 weeks and is determined by the clinical picture of the disease.

In the treatment of chronic venous insufficiency, accompanied by trophic disorders (Ulcera cruris) — in/10 ml 3 times a week. The duration of therapy - no more than 4ned and is determined by the clinical picture of the disease. An important additional measure aimed at preventing peripheral "venous" edema is the imposition of a pressure bandage with an elastic bandage.

The presence of local trophic disorders of tissues recommended simultaneous therapy drugs Solkoseril jelly, and then Solcoseryl ointment.

In the treatment of ischemic and hemorrhagic strokes in severe and extremely severe form as the main course-in / in 10 or 20 ml, respectively, daily for 10 days. Upon completion of the main course-I/m or I / 2 ml for 30 days.

Craniocerebral trauma (severe brain injury) — in/1000 mg daily for 5 days.

If the / drug administration is not possible, the drug can be administered in/m, usually 2 ml per day in undiluted form.

In/in the application of undiluted drug it must be administered slowly, because it is a hypertensive solution.

Packaging:

• Comes in original packaging. Item is brand new and unopened.

Storage:

• Keep away from direct sunlight.
• Keep locked and away from children.
• Store in dry place at room temperature.
• Do not exceed storage temperature higher than 25 C

Important notice- the outer box design may vary before prior notice!